Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 250

1.

Use of phosphate-binders and risk of infection-related and all-cause mortality in patients undergoing hemodialysis: The Q-Cohort Study.

Yamada S, Tokumoto M, Taniguchi M, Yoshida H, Arase H, Tatsumoto N, Hirakata H, Kitazono T, Tsuruya K.

Sci Rep. 2018 Jul 30;8(1):11387. doi: 10.1038/s41598-018-29757-0.

2.

Study on Dialysis Session Length and Mortality in Maintenance Hemodialysis Patients: The Q-Cohort Study.

Fujisaki K, Tanaka S, Taniguchi M, Matsukuma Y, Masutani K, Hirakata H, Kitazono T, Tsuruya K.

Nephron. 2018;139(4):305-312. doi: 10.1159/000489680. Epub 2018 Jun 7.

PMID:
29879708
3.

Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide.

Nakayama M, Tani Y, Zhu WJ, Watanabe K, Yokoyama K, Fukagawa M, Akiba T, Wolf M, Hirakata H.

Kidney Int Rep. 2017 Nov 3;3(2):364-373. doi: 10.1016/j.ekir.2017.10.016. eCollection 2018 Mar.

4.

Association of geriatric nutritional risk index with infection-related mortality in patients undergoing hemodialysis: The Q-Cohort Study.

Matsukuma Y, Tanaka S, Taniguchi M, Nakano T, Masutani K, Hirakata H, Kitazono T, Tsuruya K.

Clin Nutr. 2018 Feb 1. pii: S0261-5614(18)30037-2. doi: 10.1016/j.clnu.2018.01.019. [Epub ahead of print]

PMID:
29398335
5.

Hemoglobin concentration and the risk of hemorrhagic and ischemic stroke in patients undergoing hemodialysis: the Q-cohort study.

Yotsueda R, Tanaka S, Taniguchi M, Fujisaki K, Torisu K, Masutani K, Hirakata H, Kitazono T, Tsuruya K.

Nephrol Dial Transplant. 2018 May 1;33(5):856-864. doi: 10.1093/ndt/gfx305.

PMID:
29237088
6.

Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate.

Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Otoguro T, Yamada K, Nagamine Y, Fishbane S, Hirakata H.

Kidney Int Rep. 2017 Jan 5;2(3):359-365. doi: 10.1016/j.ekir.2016.12.005. eCollection 2017 May.

7.

Secular trends in the incidence of end-stage renal disease and its risk factors in Japanese patients with immunoglobulin A nephropathy.

Tanaka S, Ninomiya T, Katafuchi R, Masutani K, Tsuchimoto A, Tokumoto M, Hirakata H, Ooboshi H, Kitazono T, Tsuruya K.

Nephrol Dial Transplant. 2018 Jun 1;33(6):963-971. doi: 10.1093/ndt/gfx223.

PMID:
28992313
8.

Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).

Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I.

Clin Exp Nephrol. 2018 Feb;22(1):85-86. doi: 10.1007/s10157-017-1461-2. No abstract available.

PMID:
28875480
9.

Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).

Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I.

Clin Exp Nephrol. 2018 Feb;22(1):78-84. doi: 10.1007/s10157-017-1427-4. Epub 2017 Jun 28. Erratum in: Clin Exp Nephrol. 2017 Sep 5;:.

10.

Modified Creatinine Index and the Risk of Bone Fracture in Patients Undergoing Hemodialysis: The Q-Cohort Study.

Yamada S, Taniguchi M, Tokumoto M, Yoshitomi R, Yoshida H, Tatsumoto N, Hirakata H, Fujimi S, Kitazono T, Tsuruya K.

Am J Kidney Dis. 2017 Aug;70(2):270-280. doi: 10.1053/j.ajkd.2017.01.052. Epub 2017 Apr 25.

PMID:
28450093
11.

Cardiothoracic Ratio and All-Cause Mortality and Cardiovascular Disease Events in Hemodialysis Patients: The Q-Cohort Study.

Yotsueda R, Taniguchi M, Tanaka S, Eriguchi M, Fujisaki K, Torisu K, Masutani K, Hirakata H, Kitazono T, Tsuruya K.

Am J Kidney Dis. 2017 Jul;70(1):84-92. doi: 10.1053/j.ajkd.2016.11.026. Epub 2017 Feb 10.

PMID:
28196648
12.

Effect of Predialysis Recombinant Human Erythropoietin on Early Survival After Hemodialysis Initiation in Patients With Chronic Kidney Disease: Co-JET Study.

Watanabe Y, Akizawa T, Saito A, Gejyo F, Suzuki M, Nishizawa Y, Tomino Y, Tsubakihara Y, Akiba T, Hirakata H, Kawanishi H, Bessho M, Udagawa Y, Aoki K, Uemura Y, Ohashi Y; Co-JET Study Group.

Ther Apher Dial. 2016 Dec;20(6):598-607. doi: 10.1111/1744-9987.12425. Epub 2016 Dec 7.

PMID:
27928910
13.

A J-shaped association between serum uric acid levels and poor renal survival in female patients with IgA nephropathy.

Matsukuma Y, Masutani K, Tanaka S, Tsuchimoto A, Fujisaki K, Torisu K, Katafuchi R, Hirakata H, Tsuruya K, Kitazono T.

Hypertens Res. 2017 Mar;40(3):291-297. doi: 10.1038/hr.2016.134. Epub 2016 Oct 13.

PMID:
27733763
14.

Association Between Serum Phosphate Levels and Stroke Risk in Patients Undergoing Hemodialysis: The Q-Cohort Study.

Yamada S, Tsuruya K, Taniguchi M, Tokumoto M, Fujisaki K, Hirakata H, Fujimi S, Kitazono T.

Stroke. 2016 Sep;47(9):2189-96. doi: 10.1161/STROKEAHA.116.013195. Epub 2016 Aug 9.

PMID:
27507862
15.

Design and baseline characteristics of the LANDMARK study.

Ogata H, Fukagawa M, Hirakata H, Kaneda H, Kagimura T, Akizawa T; LANDMARK Study Group.

Clin Exp Nephrol. 2017 Jun;21(3):531-537. doi: 10.1007/s10157-016-1310-8. Epub 2016 Jul 12.

16.

The Fukuoka Kidney disease Registry (FKR) Study: design and methods.

Tanaka S, Ninomiya T, Fujisaki K, Yoshida H, Nagata M, Masutani K, Tokumoto M, Mitsuiki K, Hirakata H, Fujimi S, Kiyohara Y, Kitazono T, Tsuruya K; Fukuoka Kidney disease Registry (FKR) Study Collaboration Group.

Clin Exp Nephrol. 2017 Jun;21(3):465-473. doi: 10.1007/s10157-016-1294-4. Epub 2016 Jun 23.

PMID:
27339444
17.
18.

Comparison of oral versus intravenous vitamin D receptor activator in reducing infection-related mortality in hemodialysis patients: the Q-Cohort Study.

Tanaka S, Ninomiya T, Taniguchi M, Fujisaki K, Tokumoto M, Hirakata H, Ooboshi H, Kitazono T, Tsuruya K.

Nephrol Dial Transplant. 2016 Jul;31(7):1152-60. doi: 10.1093/ndt/gfw205. Epub 2016 May 27.

PMID:
27235424
19.

A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study.

Akizawa T, Tsubakihara Y, Hirakata H, Watanabe Y, Hase H, Nishi S, Babazono T, Kumagai M, Katakura S, Uemura Y, Ohashi Y; JET-STREAM Study Group.

Clin Exp Nephrol. 2016 Dec;20(6):885-895. Epub 2016 Jan 16.

20.

Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial.

Masutani K, Tsuchimoto A, Yamada T, Hirakawa M, Mitsuiki K, Katafuchi R, Hirakata H, Kitazono T, Tsuruya K; West Japan Study Group for Therapy of IgA Nephropathy Investigators.

Clin Exp Nephrol. 2016 Dec;20(6):896-903. Epub 2016 Jan 13.

PMID:
26758039

Supplemental Content

Loading ...
Support Center